TipRanks
Go Ultimate55% OFF

Aptamer Group Plc (APTA) AI Stock Analysis

12 Followers
GB:APTA

Aptamer Group Plc

(LSE:APTA)

Select Model
Rating:40Underperform
Price Target:GBX 0.27â–¼(-4.91% Downside)
Action:reiterated
Date:10/15/26

Aptamer Group receives a highly cautious overall score of 40, heavily weighed down by severe unprofitability, persistent cash burn, and a strong technical downtrend. While the company's nearly debt-free balance sheet provides a vital near-term liquidity cushion, the absence of positive operating cash flow and deep negative margins make it a highly speculative asset.

Positive Factors
Strengthened balance sheetHigher equity, expanded assets, and very low leverage provide a stronger financial cushion than in prior years. This reduces debt-related pressure and gives Aptamer Group greater flexibility to support operations while it works toward sustainable profitability.
Negative Factors
Persistent deep lossesThe company has not yet demonstrated a path to breakeven, and losses remain very large relative to revenue. Persistent negative profitability limits internally generated capital, weakens shareholder returns, and makes successful revenue scaling essential to long-term viability.

Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)

-80%-60%-40%-20%0%20%40%GB:APTA-65.24%EWC+21.74%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 9.88M
Dividend Yield
―
Average Volume (3M)
6.85M
Price to Earnings (P/E)
-9.5
Beta (1Y)
0.34
Revenue Growth
28.35%
EPS Growth
57.14%
Country
UK
Employees
34
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Aptamer Group Plc Business Overview & Revenue Model

Company Description

Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolv...

Aptamer Group Plc Financial Statement Overview

Summary

Significant operational challenges drive a low score, highlighted by a -120.6% net profit margin and deep negative cash flow. While top-line revenue improved to 1.54 million and the balance sheet is defensive with minimal debt (0.03 debt-to-equity), ongoing cash burn poses a substantial liquidity risk.

Income Statement

25Negative

Balance Sheet

65Positive

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2022
Income Statement
Total Revenue1.54M1.54M1.20M860.00K4.04M1.75M
Gross Profit573.00K573.00K350.00K250.00K2.69M359.00K
EBITDA-2.60M-2.60M-2.28M-2.81M-2.20M-7.36M
Net Income-1.86M-1.86M-2.42M-2.96M-2.09M-7.84M
Balance Sheet
Total Assets7.18M7.18M2.83M2.77M11.52M2.75M
Cash, Cash Equivalents and Short-Term Investments4.36M4.36M1.06M870.00K6.69M234.00K
Total Debt170.00K170.00K491.00K817.00K1.31M1.08M
Total Liabilities1.44M1.44M1.45M1.88M3.47M2.45M
Stockholders Equity5.74M5.74M1.38M887.00K8.05M304.00K
Cash Flow
Free Cash Flow-2.30M-2.30M-2.01M-2.41M-2.79M-6.09M
Operating Cash Flow-2.13M-2.13M-2.00M-2.28M-2.38M-4.06M
Investing Cash Flow-253.00K-253.00K-92.00K-122.00K-418.00K-2.03M
Financing Cash Flow5.68M5.68M2.28M3.04M9.12M-365.00K

Aptamer Group Plc Technical Analysis

Technical Analysis SentimentNegative
Last Price0.28

Price Trends

50DMA0.33Negative
100DMA0.39Negative
200DMA0.55Negative

Market Momentum

MACD-0.01Positive
RSI18.44Positive
STOCH16.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.33, and below the 200-day MA of 0.55, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 18.44 is Positive, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:APTA.

Aptamer Group Plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:APTA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:BVXPGB:BVXP89OutperformGBP 107.11M13.9667.81%7.41%-1.10%0.32%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:AVCTGB:AVCT43NeutralGBP 279.90M-6.30-1293.07%―――
GB:OBDGB:OBD40UnderperformGBP 13.78M-0.26-451.74%―33.37%86.41%
GB:APTAGB:APTA40UnderperformGBP 9.88M-9.50-46.61%―28.35%57.14%
GB:FABGB:FAB35UnderperformGBP 7.51M-5.81-97.87%―7.38%44.13%
GB:ARECGB:AREC33UnderperformGBP 37.37M155.003.75%―――

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%GB:APTAGB:AVCTGB:BVXPGB:OBDGB:FABGB:ARECDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:APTA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:APTAAptamer Group Plc0.28-0.53-65.24%
GB:AVCTAvacta Group plc55.60-14.90-21.13%
GB:BVXPBioventix plc1930.00-34.85-1.77%
GB:OBDOxford BioDynamics0.11-0.19-63.33%
GB:FABFusion Antibodies Plc5.75-7.25-55.77%
GB:ARECArecor Therapeutics PLC77.502.503.33%

Aptamer Group Plc Corporate Events

Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing

Aptamer Group lifts revenue and cash as licensing and pharma demand deepen

Positive
Oct 13, 2026

Aptamer Group reported full-year revenue of £1.5 million, up 28% year-on-year, supported by growing demand for its Optimer technology and repeat work with multiple top 20 pharmaceutical companies. A £4.1 million equity raise lifted the year...

Business Operations and StrategyFinancial Disclosures

Aptamer Group Sets Analyst and Investor Meetings for Full-Year Results

Positive
Oct 7, 2026

Aptamer Group plc plans to release its full-year results for the period ended 30 June 2026 on 13 October, alongside a scheduled online briefing for analysts hosted by Chief Executive Dr Arron Tolley and Chief Financial Officer Andrew Rapson. The comp...

Business Operations and Strategy

Aptamer Group Adds Cavendish as Joint Corporate Broker to Bolster Investor Reach

Positive
Aug 20, 2026

Aptamer Group plc has appointed Cavendish Capital Markets as joint corporate broker alongside Turner Pope Investments, strengthening its capital markets advisory team. The move aims to expand research coverage and deepen institutional engagement as t...

Business Operations and StrategyExecutive/Board Changes

Aptamer Group boosts director stakes and launches major incentive scheme

Positive
Aug 14, 2026

Aptamer Group has issued 12,936,511 new ordinary shares to remunerate Non-Executive Chairman Adam Hargreaves, via Pathcelerate Limited, and Non-Executive Director Tim Sykes, for services during the year to 30 June 2026. The share-based payments lift...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 15, 2026